Amphivena to expand clinical program, T cell engager pipeline with $62M series C

Amphivena Therapeutics Inc. will use its $62 million series C to advance its lead candidate in solid tumors and build out its T cell engager portfolio. The round, closed Tuesday, was co-led by new investors NanoDimension and Qiming Venture Partners.

Amphivena was formed via a 2013 build-to-buy deal between Affimed N.V. (NASDAQ:AFMD), MPM Capital -- which led the biotech’s $19.5 million A round -- and Janssen Biotech Inc., which decided in 2016 not to exercise its option to acquire Amphivena. The company has a license to Affimed’s AMV564, a bivalent bispecific T cell engager that targets CD33 on cancer cells and CD3 on T cells...